Clinical Trials &
R&D Tax Credits
Bridging the gap between medical innovation and IRS Section 41 regulations. Understanding the fiscal impact of scientific experimentation.
The Intersection of Science & Law
Detailed Insight
Clinical trials are the engine of medical advancement, representing a systematic investigation into the safety and efficacy of new drugs, devices, and treatments. In the context of R&D tax credit law, these trials are not merely medical procedures but are viewed as a rigorous "process of experimentation." The intricate phases of testing—ranging from initial safety screenings in Phase I to large-scale efficacy studies in Phase III—inherently involve significant technical uncertainty. Because the outcome (FDA approval or drug viability) is unknown at the outset, the financial resources dedicated to hypothesis testing, protocol development, and data analysis align perfectly with the legislative intent of the Research & Development Tax Credit.
From an IRS regulatory standpoint, Clinical Trials are a prime candidate for Section 41 incentives. The regulations specifically reward activities that rely on the hard sciences (biology, chemistry, pharmacology) to eliminate technical uncertainty. Since clinical trials require the formulation of hypotheses, testing under controlled conditions, and refining methodologies based on results, they satisfy the statutory "Four-Part Test." Consequently, the substantial costs associated with these trials—including investigator fees, CRO (Contract Research Organization) expenses, and internal clinical management wages—can often be captured to offset tax liability, providing critical capital to sustain long-term innovation cycles.
The "Four-Part Test" Framework
For a Clinical Trial to qualify for the credit, it must satisfy four specific IRS criteria. Click each card to analyze how typical trial activities align with the law.
Trial Phases: Cost vs. Uncertainty
Visualizing why earlier phases often carry higher "Technical Uncertainty" (a key R&D metric) while later phases drive "Qualified Cost" volume.
Example: BioPharmX Oncology Study
BioPharmX initiates a Phase II trial for a novel immunotherapy agent. The goal is to determine the optimal dosage and safety profile.
- ✅ Uncertainty: Unknown toxicity levels and metabolic reaction rates.
- ✅ Process: Iterative dosing protocols (3+3 design), blood sample analysis, and protocol amendments based on patient response.
- 💰 Result: Wages for Clinical Directors, payments to research hospitals (CROs) for testing, and supply costs for the drug synthesis are claimed as QREs.
Qualified Expense Breakdown
R&D Benefit Estimator
Adjust the slider to estimate potential net tax credits based on typical Clinical Trial cost structures.
Note: This model assumes a blend of internal labor and 65% eligible Contractor costs, estimating a conservative 6-10% net credit yield on gross spend.
Documentation
Gather FDA protocols, Informed Consent Forms (ICF), and Institutional Review Board (IRB) correspondence to prove the "Process of Experimentation."
Tracking
Implement project accounting codes specific to clinical phases. Separate "Standard of Care" costs from "Investigational" costs.
Consultation
Engage tax specialists to review CRO contracts. Ensure you own the rights to the research to claim the expenses.
Navigating the Intersection of Regulatory Science and Tax Policy: Clinical Trials as Qualified Research Activities under IRC Section 41
I. Executive Summary: Clinical Trials in the Context of IRC §41
Clinical trials represent the culminating and often most capital-intensive segment of research and development (R&D) within the life sciences sector. For federal tax purposes, expenditures related to these trials are critically scrutinized under Internal Revenue Code (IRC) Section 41, which governs the Credit for Increasing Research Activities, commonly known as the R&D Tax Credit. Activities within the rigorous, systematic framework of clinical trials—which are mandated by the Food and Drug Administration (FDA) prior to market approval—are generally considered Qualified Research Activities (QRAs) because they inherently meet the statutory requirement for a “process of experimentation”.1 This process is essential for resolving profound technical uncertainties surrounding a new drug or biologic’s capability, optimal design, safety profile, and clinical methodology.3
The eligibility of costs incurred during clinical development, categorized as Qualified Research Expenses (QREs), depends heavily on the specific development phase. Strategically, IRS guidance provides a crucial distinction, establishing a compliance safe harbor: QREs attributable to activities occurring during Phase I and Phase II clinical trials should generally not be challenged by examiners during an audit, provided documentation standards are met.5 This directive recognizes that the highest degree of fundamental scientific uncertainty regarding the product’s function and appropriate design exists in the early stages of human testing.3 Conversely, expenditures related to late-stage (Phase III) and post-approval (Phase IV) trials carry a higher audit risk, necessitating meticulous documentation to demonstrate that the activity is focused on resolving new or unforeseen technical issues, rather than merely routine quality control or large-scale data verification.6
II. The Meaning and Importance of Clinical Trials in US R&D Tax Law
A. Defining Clinical Trials: Regulatory Mandate and Scientific Purpose
Clinical trials are formal, structured scientific investigations testing potential treatments, such as drugs, medical devices, or biologics (e.g., vaccines or gene therapies), in human volunteers, typically after initial toxicity studies in laboratory animals have yielded acceptable safety profiles.1 These trials are mandatory for securing FDA market approval and are conducted in progressive, systematic stages known as phases. Phase I trials, involving approximately 20 to 80 healthy individuals, are primarily focused on safety, determining initial dosage, and analyzing pharmacokinetics (how the drug is absorbed, metabolized, and excreted).7 Phase II trials expand the study to approximately 100 to 300 patients with the target condition, seeking to determine the effectiveness (efficacy) of the drug and refine the optimal dosage and method of use.7 Phase III studies represent the final, large-scale investigation, involving several hundred to a few thousand participants, to confirm safety, effectiveness, and comprehensive risk/benefit profiles across diverse populations.5 For R&D tax purposes, this mandatory, systematic progression fulfills the most critical requirement of the four-part test for qualified research: the “Process of Experimentation.” The structured protocol is the mechanism by which the taxpayer systematically attempts to resolve the technological uncertainty inherent in translating a candidate compound from the laboratory into a viable, effective human therapeutic.2
B. The Strategic Importance of R&D Tax Incentives for Biopharmaceutical Innovation
The R&D Tax Credit (IRC §41), which was made permanent by the PATH Act of 2015, serves as a crucial financial incentive for the biopharmaceutical industry, enabling companies to offset the immense capital costs and high failure rates associated with clinical development.9 This credit provides tax savings and enhances cash flow, allowing companies to reinvest resources into further high-risk research and innovation.10 This role as a financial catalyst is particularly vital for projects targeting small patient populations, such as Orphan Drugs, where the credit can significantly improve the economic viability of otherwise unprofitable research activities.11 Furthermore, the financial relief provided by the IRC §41 credit is particularly strategic in light of changes to IRC Section 174, which now generally requires the capitalization and amortization of domestic Research and Experimental (R&E) expenditures over five years, rather than allowing immediate deduction.2 While amortization reduces the immediate deductibility of R&E costs, the R&D Tax Credit provides an immediate dollar-for-dollar reduction in tax liability based on qualifying costs, mitigating the negative cash flow impact caused by the mandatory Section 174 capitalization rules and sustaining investment in ongoing clinical trials.2
III. The Statutory Framework: Applying the IRC §41 Four-Part Test to Clinical Experimentation
To qualify for the R&D tax credit, clinical trial activities and associated expenses must satisfy the four-part test defined in IRC §41(d).4 The regulatory definition requires a business component (the drug or biologic) to meet all criteria simultaneously.
A. Criterion 1: Permitted Purpose (Function, Performance, Reliability, or Quality)
The research must be conducted for a “qualified purpose,” meaning the development or improvement of a business component (product or process) must relate to a new or improved function, performance, reliability, or quality.4 Clinical trials inherently satisfy this criterion. The purpose of testing a new drug is to establish a new function (treating a disease for which no adequate treatment exists) or significantly improved performance (greater efficacy, safety, or quality) compared to existing therapies. The focus must be on these functional aspects, ensuring that the research is not related merely to excluded aesthetic factors such such as style, taste, cosmetic, or seasonal design.3
B. Criterion 2: Technological in Nature
The research activity must intend to discover information that is technological in nature, relying upon the established principles of a hard science.4 Drug and biologic development relies fundamentally on established principles of biology, chemistry, and biostatistics.14 Clinical trials apply the scientific method in a highly controlled environment to study complex human biological systems and pharmacologic responses. The systematic measurement of efficacy endpoints, drug absorption, and adverse event profiles through FDA-mandated protocols demonstrates a direct reliance on scientific principles, confirming the activity is technological in nature.1
C. Criterion 3: Technical Uncertainty
Technical uncertainty must exist at the project’s outset concerning the capability, method, or appropriate design of the business component.4 In the context of clinical development, uncertainty is paramount and is, in fact, the justification for the entire trial process.1 Pre-clinical data provides only an initial indication of potential, but uncertainty persists because the available information does not establish the product’s behavior in humans.3 Specifically, uncertainty exists regarding:
- Capability: Whether the drug will perform as intended (efficacy) in a live, complex human system.
- Method: The specific dosing schedule, administration route, or delivery mechanism required for optimal results.
- Appropriate Design: The protocol parameters, patient stratification criteria, or biomarker endpoints necessary to validate success.3
It is important to recognize that the level of technical uncertainty generally diminishes as the trial progresses. Uncertainty is typically highest during Phases I and II, where initial human safety and effectiveness are unknown. By Phase III, core uncertainty surrounding the drug’s fundamental capability and method may have resolved. Therefore, for Phase III activities to qualify, the taxpayer must demonstrate that the experimentation is still focused on resolving specific, residual uncertainties—such as refining dosage for sub-populations or addressing unforeseen safety signals—rather than simply performing routine data collection for regulatory submission.
D. Criterion 4: The Process of Experimentation
The activity must involve a systematic process designed to attempt to resolve the technical uncertainties identified in Criterion 3, often requiring the evaluation of alternatives.2 Clinical trials are fundamentally systematic. The progression from Phase I (safety focus) to Phase II (efficacy focus) and Phase III (large-scale confirmation) constitutes a structured, evaluative process required by regulatory bodies.5 Specific activities within this process that qualify include: the development and validation of novel trial protocols, such as adaptive trial arms or decentralized models; the design of new patient-stratification algorithms or predictive retention models; and the side-by-side validation of alternative experimental designs or novel biomarker tracking methods.2 This systematic evaluation, involving multiple alternatives or iterative refinement, is key to satisfying the experimentation requirement.
IV. Regulatory Nexus: IRS Guidance on Qualifying Clinical Trial Stages and Audit Strategy
The high volume of R&D expenses claimed by pharmaceutical and biotechnology companies necessitated specific guidance from the IRS regarding the eligibility of clinical trial costs. This guidance, provided in the form of internal directives, establishes clear boundaries for audit risk based on the phase of the trial.
A. The IRS Internal Directive and the De Facto Safe Harbor
The development process for pharmaceutical drugs and therapeutic biologics is generally segmented into four stages, with Stage 2 encompassing the Clinical Trial Stage.5 Crucially, the IRS guidance instructs examiners that they should generally not challenge the amount of QREs taken by a taxpayer to the extent those expenses are for qualified research activities that occur during Phase I and Phase II of the Clinical Trial Stage (Stage 2).5 This directive effectively creates a low-risk, non-challenge zone for early-stage human testing expenditures. The basis for this is the implicit recognition that Phase I and Phase II trials—focused on establishing safety, dose range, pharmacokinetics, and initial efficacy in smaller cohorts (20 to 500 patients)—are unquestionably dominated by the resolution of technical uncertainties.7 The activities performed during these stages are inherently experimental in the truest sense of the law.5
B. Risk Allocation in Phase III and IV Activities
Activities conducted during Phase III and the subsequent Post Approval Stage (Stage 4), which includes Phase IV trials, are not covered by the general non-challenge directive, except for specific trials required by the FDA relating to Accelerated Approvals.5 Phase III trials, which involve large-scale data gathering across thousands of patients, and Phase IV trials, which focus on long-term surveillance and routine monitoring, carry a significantly higher audit risk. The primary concern during these later stages is the application of the statutory exclusions under IRC §41(d)(4). Since Phase III activities primarily function as comprehensive verification for regulatory submission, they may be reclassified as:
- Post-Production Activities: Activities conducted after commercial production begins (a risk if Phase III costs are incurred close to or following regulatory filing).5
- Routine Testing or Quality Control: Activities designed merely to ensure the product meets established standards, rather than resolving new uncertainty.6
To successfully claim QREs for Phase III activities, the taxpayer must actively document ongoing technical uncertainty and the systematic processes used to resolve that specific uncertainty, such as unexpected sub-group analyses, adaptive changes to the protocol based on emerging data, or redesign efforts aimed at unforeseen manufacturing or dosage challenges. Without this substantiation, Phase III and IV costs are vulnerable to disallowance by examiners.
The following table summarizes the typical risk profile for clinical expenses based on phase, directly aligning audit strategy with the underlying technical objective:
Clinical Trial Phase Qualification Table
| Clinical Trial Phase (Stage 2) | Primary Objective | Technical Uncertainty Level | IRS Audit Posture (Internal Guidance) |
| Phase I | Establishing safety, dose range, and pharmacokinetics 7 | High (Fundamental human mechanism) | Generally not challenged (Strong presumption of qualification) 5 |
| Phase II | Determining effectiveness, refining optimal method, and dosage 7 | High/Moderate (Efficacy confirmation) | Generally not challenged (Strong presumption of qualification) 5 |
| Phase III | Large-scale validation, comparative efficacy, and comprehensive safety 7 | Moderate/Low (Verification for regulatory submission) | Subject to challenge; must document resolution of new technical uncertainty or adaptive design 5 |
| Phase IV (Stage 4) | Long-term surveillance, routine monitoring, and marketing support 5 | Low (Routine/Post-production monitoring) | Generally excluded (Fails technical uncertainty/process of experimentation test) 5 |
V. Qualified Research Expenses (QREs) and Substantiation in Clinical Trials
Qualified Research Expenses (QREs) are central to the calculation of the R&D tax credit.13 For clinical trials, QREs typically fall into three categories: wages, supplies, and contract research expenses (CREs). Accurate substantiation requires meticulous segregation of these costs from general and administrative (G&A) overhead.13
A. QRE Categories and Clinical Applications
- Wages for Qualified Services: This includes compensation paid to employees who directly perform qualified research, directly supervise such research, or directly support it.2 In the clinical context, this encompasses salaries for essential personnel such as Clinical Scientists, Biostatisticians developing analytical methodologies, Data Managers handling experimental data streams, and Trial-Tech Engineers developing prototype digital tools.16 The labor must be performed in the United States to qualify.13
- Supplies: Costs for tangible personal property consumed or used in the conduct of qualified research.2 It is paramount that these materials are consumed in the experimentation process and not capitalized as depreciable property.13 Examples in clinical trials include disposable sensor modules, patient monitoring kits, reagents, lab consumables used for biomarker analysis, and trial-platform licenses.16
- Contract Research Expenses (CREs): Taxpayers may claim 65% of amounts paid or incurred to any person (other than an employee) for qualified research conducted on the taxpayer’s behalf.2 This often represents a significant portion of clinical trial costs, covering fees paid to Contract Research Organizations (CROs) for executing pilot cohorts, specialized external analytics vendor contracts, or fees paid to digital platform vendors for upgrading experimental data capture systems.16
B. Illustrative Example: Calculation and Substantiation of QREs in a Phase IIb Trial
Consider a biotechnology company conducting a complex Phase IIb adaptive clinical trial for a novel therapeutic designed to target a rare dermatological condition. The trial is designed to systematically evaluate alternative dosing regimens and delivery methods (Criterion 4) due to technical uncertainty regarding the appropriate systemic exposure needed for efficacy (Criterion 3).
The Activity: The company introduces an adaptive trial arm that requires developing a novel patient-stratification algorithm and integrating a remote digital monitoring platform with wearable sensors to track real-time patient biometric responses and adjust dosing protocols accordingly.16 This systematic evaluation of multiple alternatives satisfies the process of experimentation.
Qualified Research Expenses (QRE) Breakdown:
- Wages: The salary paid to the company’s internal biostatistician team for developing and validating the proprietary patient-stratification algorithms is fully qualifying.16 Furthermore, the wages paid to the clinical development manager who directly supervises the experimental design changes in the adaptive trial arms also qualify.13
- Supplies: The cost of disposable sensor modules and patient-monitoring kits provided to the 300-patient cohort for the collection of experimental biomarker data are considered consumable supplies.16 Additionally, prototype digital tools and trial-platform licenses specifically used to support the qualified research are qualifying expenses.16
- Contract Research: 65% of the fees paid to the CRO for executing the specialized pilot cohort that tested two alternative digital data capture methods before the main trial rollout qualifies. Similarly, 65% of the contract fees paid to an external vendor specializing in predictive retention modeling to analyze the initial experimental data streams are included.16
This example demonstrates the necessity of segregating costs related to innovation (algorithm development, platform integration, pilot cohort execution) from routine clinical care or administrative tasks (patient meals, general site management).
VI. Policy Recommendations and Next Steps for Clarification
To further clarify and explain Clinical Trials’ use more fully within the context of IRC §41, regulatory bodies should focus on providing formal, prospective guidance that aligns tax law with the evolution of modern clinical science and minimizes ongoing audit risk for taxpayers.
A. Next Step 1: Codify the Phase I/II Presumption of Qualification
Currently, the presumption that QREs from Phase I and Phase II trials generally will not be challenged rests upon an internal IRS directive.5 While highly beneficial, reliance on internal guidance introduces a degree of uncertainty. The most significant action would be for the Treasury Department and IRS to issue formal, binding regulations that explicitly codify the presumptive qualification of QREs incurred during Phase I and Phase II clinical trials for novel drugs and biologics. This formal codification would provide essential stability and predictability for long-term R&D capital planning in the life sciences industry, offering a firm legal foundation for these claims rather than relying on evolving administrative policy.
B. Next Step 2: Update Guidance on Modern Trial Design and Digital QREs
The IRS Audit Techniques Guide and existing guidance lack sufficient specificity regarding the rapidly expanding use of digital health technologies and decentralized trial designs.16 New guidance should address the qualification of expenses related to advanced methodologies, such as adaptive trial arms, remote monitoring platforms, specialized software (e.g., e-CRF upgrades, simulation tools), and artificial intelligence used for patient stratification and real-time analytics.16 Specific clarification is needed to definitively distinguish licenses and fees for technological platforms used for experimental data capture and analysis (which should qualify as supplies or computer lease costs 16) from general-purpose software or routine administrative IT costs, thereby minimizing ambiguity during examination.17
C. Next Step 3: Legislative Advocacy for R&E Expensing Restoration (IRC §174)
While separate from IRC §41, the overall financial health of clinical development is profoundly affected by IRC Section 174. The current requirement, mandated by the 2017 Tax Cuts and Jobs Act, for taxpayers to capitalize and amortize domestic R&E expenditures over five years significantly reduces the immediate cash flow available to fund capital-intensive clinical trial stages.2 Legislative action to reinstate the ability to immediately deduct (expense) all domestic R&E costs in the year incurred is a critical economic step. Restoring immediate expensing under IRC Section 174 would fully align tax policy with the national goal of fostering innovation, ensuring that companies have the maximum possible capital to advance promising therapeutics from the safety of Phase I through the confirmation required in Phase III.9
Are you eligible?
Why choose us?
Pass an Audit?
What is the R&D Tax Credit?
The Research & Experimentation Tax Credit (or R&D Tax Credit), is a general business tax credit under Internal Revenue Code section 41 for companies that incur research and development (R&D) costs in the United States. The credits are a tax incentive for performing qualified research in the United States, resulting in a credit to a tax return. For the first three years of R&D claims, 6% of the total qualified research expenses (QRE) form the gross credit. In the 4th year of claims and beyond, a base amount is calculated, and an adjusted expense line is multiplied times 14%. Click here to learn more.
Never miss a deadline again
Stay up to date on IRS processes
Discover R&D in your industry
R&D Tax Credit Preparation Services
Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed provides state and federal R&D tax credit preparation and audit services to all 50 states.
If you have any questions or need further assistance, please call or email our CEO, Damian Smyth on (800) 986-4725.
Feel free to book a quick teleconference with one of our national R&D tax credit specialists at a time that is convenient for you.
R&D Tax Credit Audit Advisory Services
creditARMOR is a sophisticated R&D tax credit insurance and AI-driven risk management platform. It mitigates audit exposure by covering defense expenses, including CPA, tax attorney, and specialist consultant fees—delivering robust, compliant support for R&D credit claims. Click here for more information about R&D tax credit management and implementation.
Our Fees
Swanson Reed offers R&D tax credit preparation and audit services at our hourly rates of between $195 – $395 per hour. We are also able offer fixed fees and success fees in special circumstances. Learn more at https://www.swansonreed.com/about-us/research-tax-credit-consulting/our-fees/
Choose your state
